Moringa coagulant as a stabilizer for amorphous solids: Part i

AAPS PharmSciTech

Volumn 13, Issue 2, 2012, Pages 400-410

  Bhende, Santosh ^a   Jadhav, Namdeo ^a  

^a BHARATI VIDYAPEETH COLLEGE OF PHARMACY   (India)

Author keywords

amorphous state; arginine; drug coagulant interactions; moringa coagulant; stabilization

Indexed keywords

ARGININE; BIOPOLYMER; COAGULATING AGENT; FELODIPINE; GLASS; IBUPROFEN; MELOXICAM; MORINGA OLEIFERA EXTRACT;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; DRUG STABILITY; GLASS TRANSITION TEMPERATURE; HYDROGEN BOND; IN VITRO STUDY; INFRARED SPECTROSCOPY; MOLECULAR DOCKING; MORINGA OLEIFERA; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SPRAY DRYING; STATIC ELECTRICITY; THERMODYNAMICS; X RAY POWDER DIFFRACTION;

ARGININE; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; COAGULANTS; CRYSTALLOGRAPHY, X-RAY; DRUG STABILITY; EXCIPIENTS; FELODIPINE; HYDROGEN BONDING; IBUPROFEN; KINETICS; MICROSCOPY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MORINGA OLEIFERA; PLANT PROTEINS; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TECHNOLOGY, PHARMACEUTICAL; THIAZINES; THIAZOLES; TRANSITION TEMPERATURE; X-RAY DIFFRACTION;

EID: 84862876644     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-012-9755-x     Document Type: Article

References (43)

1. C Ahlneck G Zografi 1990 The molecular basis of moisture on the physical and chemical stability of drugs in the solid state Int J Pharm 62 87 95 10.1016/0378-5173(90)90221-O 1:CAS:528:DyaK3cXlslyjurg%3D (Pubitemid 20261777)
2. BC Hancock K Christensen SL Shamblin 1998 Estimation the critical molecular mobility temperature (Tk) of amorphous pharmaceuticals Pharm Res 15 1649 1651 9833982 10.1023/A:1011983923386 1:CAS:528:DyaK1cXnsFSgu7Y%3D (Pubitemid 28524571)
3. M Yoshioka BC Hancock G Zografi 1994 Crystallization of indomethacin from amorphous state below and above its glass transition temperature J Pharm Sci 83 1700 1705 7891297 10.1002/jps.2600831211 1:CAS:528:DyaK2cXms1entrY%3D
4. BC Hancock SL Shamblin G Zografi 1995 Molecular mobility of amorphous pharmaceutical solids below their glass transition temperature Pharm Res 12 709 806 10.1023/A:1016292416526
5. V Pokharkar L Mandpe M Padamwar A Ambike K Mahadik A Paradkar 2006 Development, characterization and stabilization of amorphous form of a low Tg drug Powder Technol 167 20 25 10.1016/j.powtec.2006.05.012 1:CAS:528: DC%2BD28XotlKgsbs%3D (Pubitemid 44215984)
6. T Matsumoto G Zografi 1999 Physical properties of solid molecular (vinylpyrrolidone-co vinylacetate) in relation to indomethacin crystallization Pharm Res 16 1722 1728 10571278 10.1023/A:1018906132279 1:CAS:528: DyaK1MXnt1GgsL4%3D (Pubitemid 29530405)
7. R Pignatello D Spadaro MA Vandelli F Forni G Puglisi 2004 Characterization of the mechanism of interaction in ibuprofen- Eudragit RL100 coevaporates Drug Dev Ind Pharm 30 277 288 15109027 10.1081/DDC-120030421 1:CAS:528:DC%2BD2cXhvF2ltrY%3D (Pubitemid 38451752)
8. SY Lin RI Perng 1993 Solid-state interaction studies of drugs/polymers. I: Indomethacin/Eudragit E, RL or S resins STP Pharm Sci 3 465 471 1:CAS:528:DyaK2cXisFeiurY%3D (Pubitemid 24014309)
9. VV Boldyrev TP Shakhtshneider LP Burleva VA Severtsev 1994 Preparation of the disperse systems of sulphathiazole-poly(vinylpyrrolidone) by mechanical activation Drug Dev Ind Pharm 20 1103 1114 10.3109/03639049409038355 1:CAS:528:DyaK2cXisFehtb8%3D (Pubitemid 24134826)
10. TP Shakhtshneider F Danède F Capet JF Willart M Descamps L Paccou, et al. 2007 Grinding of drugs with pharmaceutical excipients at cryogenic temperatures. Part I. Cryogenic grinding of piroxicam-polyvinylpyrrolidone mixtures J Therm Anal Chem 89 699 707 10.1007/s10973-006-7958-7 1:CAS:528:DC%2BD2sXpvVCisbw%3D (Pubitemid 47351761)
11. TP Shakhtshneider F Danède F Capet JF Willart M Descamps L Paccou, et al. 2007 Grinding of drugs with pharmaceutical excipients at cryogenic temperatures. Part II. Cryogenic grinding of indomethacin-polyvinylpyrrolidone mixtures. J Therm Anal Chem 89 709 715 10.1007/s10973-006-7959-6 1:CAS:528:DC%2BD2sXpvVCisb0%3D (Pubitemid 47351762)
12. G Van den M Wuyts N Blaton R Busson P Grobet P Augustijns, et al. 2001 Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25 Eur J Pharm Sci 12 261 269 10.1016/S0928-0987(00)00173- 1
13. AA Ambike KR Mahadik AR Paradkar 2004 Stability study of amorphous valdecoxib Int J Pharm 282 151 162 15336390 10.1016/j.ijpharm.2004.06.009 1:CAS:528:DC%2BD2cXntVGhsLg%3D (Pubitemid 39178492)
14. SL Shimpi KR Mahadik AR Paradkar 2009 Study on mechanism for amorphous drug stabilization using Gelucire 50/13 Chem Pharm Bull 57 937 942 19721253 10.1248/cpb.57.937 1:CAS:528:DC%2BD1MXhtlOqtb%2FJ
15. G Alja M Uro B Marjan P Odon S Stane G Miran, et al. 2007 Vitrification from solution in restricted space: formation and stabilization of amorphous nifedipine in a nanoporous silica xerogel carrier Int J Pharm 343 131 140 10.1016/j.ijpharm.2007.05.022 (Pubitemid 47321018)
16. M Subrata P Satyanarayan S Kalpana K Pintu S Arindam G Gaurisankar, et al. 2008 Formation of physically stable amorphous phase of ibuprofen by solid state milling with kaolin Eur J Pharm Biopharm 68 346 351 10.1016/j.ejpb.2007. 06.003
17. V Ambrogi L Perioli F Marmottini C Rossi 2007 Use of Mg-Al-hydrocalcite to enhance the stability of celecoxib in amorphous form Eur J Pharm Sci 66 253 259 1:CAS:528:DC%2BD2sXkslCht7o%3D (Pubitemid 46654767)
18. GK Folkard JP Sutherland WD Grant 1990 Natural coagulant for appropriate water treatment-a novel approach Waterlines 8 4 30 32 10.3362/0262-8104.1990.020
19. A Ndabigengesere KS Narasiah BG Talbot 1995 Active agents and mechanism of coagulation of turbid waters using Moringa oleifera Water Res 29 703 710 10.1016/0043-1354(94)00161-Y 1:CAS:528:DyaK2MXjtFajtLY%3D
20. U Gassenschmidt K Jany B Tauscher H Niebergall 1995 Isolation and characterization of a flocculating protein from Moringa oleifera Lam Biochim Biophys Acta 1243 477 481 7727523 10.1016/0304-4165(94)00176-X
21. R Maikokera HM Kwaambwa 2007 Interfacial properties and fluorescence of a coagulating protein extracted from moringa oleifera seeds and its interaction with sodium dodecyl sulphate Colloids Surf B Biointerfaces 55 173 178 17207612 10.1016/j.colsurfb.2006.11.029 1:CAS:528:DC%2BD2sXitFeku7c%3D (Pubitemid 46274239)
22. Jadhav NR, Bhawale BK, Paradkar AR, Kadam SS. inventors. Novel pharmaceutical composition for solubility enhancement. Indian patent. 1883. June.28, 2010.
23. Jadhav NR, Bhende SA, More HN. Novel stabilized composition of amorphous state solids. Indian patent. 2046. July.19, 2011.
24. P Mura F Maestrelli M Cirri 2003 Ternary systems of naproxen with hydroxypropyl-b-cyclodextrin and aminoacids Int J Pharm 260 293 302 12842348 10.1016/S0378-5173(03)00265-5 1:CAS:528:DC%2BD3sXkvFektLg%3D (Pubitemid 36773926)
25. P Mura GP Bettinetti M Cirri F Maestrelli M Sorrenti L Catenacci 2005 Solid state characterization and dissolution properties of naproxen-arginine- hydroxypropyl beta-cyclodextrin ternary system Eur J Pharm Biopharm 59 99 106 15567306 10.1016/j.ejpb.2004.05.005 1:CAS:528:DC%2BD2cXhtValsrjK (Pubitemid 39573441)
26. T Arakawa Y Kita K Hajime 2008 Solubility enhancement of gluten and organic compounds by arginine Int J Pharm 355 220 223 18242019 10.1016/j.ijpharm.2007.12.009 1:CAS:528:DC%2BD1cXkt1ygsr0%3D
27. HA El-Maradny SA Mortada OA Kamel AH Hikal 2008 Characterization of ternary complexes of meloxicam-HP-CD and PVP or l-arginine prepared by the spray-drying technique Acta Pharm 58 455 466 19103579 10.2478/v10007-008-0029-9 1:CAS:528:DC%2BD1MXlsFChsw%3D%3D
28. R Ariki A Hirano T Arakawa K Shiraki 2011 Arginine increases the solubility of alkyl gallates through interaction with the aromatic ring J Biochem 149 389 394 21278386 10.1093/jb/mvr004 1:CAS:528:DC%2BC3MXjvFenu7g%3D
29. A Hirano T Kameda T Arakawa K Shiraki 2010 Arginine-assisted solubilization system for drug substances: solubility experiment and simulation J Phys Chem B 114 13455 13462 20925397 10.1021/jp101909a 1:CAS:528: DC%2BC3cXht1KhtrvN
30. M Kawano T Hatta J Hwang 2009 Enhancement of dissolution rates of amorphous silica by interaction with amino acids in solution at pH 4 Clays Clay Miner 57 161 167 10.1346/CCMN.2009.0570203 1:CAS:528:DC%2BD1MXnslSms78%3D
31. Xiaodan Q, Jing Z, Wei W, Deying C. Solubility and stability of indomethacin in arginine-assisted solubilization system. Pharm Dev Technol. 2011. doi: 10.3109/10837450.2011.595797.
32. D Bramhane N Saindane P Vavia 2011 Inclusion complexation of weakly acidic NSAID with β-cyclodextrin: selection of arginine, an amino acid, as a novel ternary component Inclusion Phenom Macrocyclic Chem 69 453 460 10.1007/s10847-010-9783-7 1:CAS:528:DC%2BC3MXivVCgtLk%3D
33. Gutzow I, Schmelzer J. Crystal research technology: the vitreous state-thermodynamics, structure, rheology, and crystallization, vol. 31. Berlin: Springer; 1996. p. 178.
34. MLF Nascimento LA Souza EB Ferreira ED Zanotto 2005 Can glass stability parameters infer glass forming ability? Journal of Non-Crystalline Solids 351 3296 3308 10.1016/j.jnoncrysol.2005.08.013 1:CAS:528:DC%2BD2MXhtVKjtrrJ (Pubitemid 41394205)
35. D Turnbull 1969 Under what conditions can a glass be formed? Contemp Phys 10 473 488 10.1080/00107516908204405 1:CAS:528:DyaE3cXhsFansA%3D%3D
36. G Chawla AK Bansal 2009 Molecular mobility and physical stability of amorphous irbesartan Sci Pharm 77 695 709 10.3797/scipharm.0806-09 1:CAS:528:DC%2BD1MXht12qurnE
37. EA Hernandez B Posada R Irizarry ME Castro 2005 Role of hydrogen bonding interactions in directing one-dimensional thiol-assisted growth of silver-based nanofibers J Phys Chem B 109 7251 7257 16851829 10.1021/jp044242n 1:CAS:528:DC%2BD2MXisVGksLc%3D (Pubitemid 40609856)
38. K Evangelos K Georgios X Aristotelis G Emmanouel 2006 Effect of hydrogen bonding interactions on the release mechanism of felodipine from nanodispersions with polyvinylpyrrolidone Eur J Pharm Biopharm 63 103 114 10.1016/j.ejpb.2006. 01.016 (Pubitemid 43776203)
39. AA Ambike KT Mahadik A Paradkar 2005 Spray-dried amorphous solid dispersions of simvastatin, a low Tg drug: in vitro and in vivo evaluations Pharm Res 22 990 998 15948043 10.1007/s11095-005-4594-z 1:CAS:528: DC%2BD2MXltVKntbo%3D (Pubitemid 40898109)
40. M Gordon JS Taylor 1952 Ideal copolymers and the second-order transitions of synthetic rubbers. I. Non-crystalline copolymers J Appl Chem 2 493 500 10.1002/jctb.5010020901 1:CAS:528:DyaG3sXjvF2ntA%3D%3D
41. W Ali AC Williams CF Rawlinson 2010 Stochiometrically governed molecular interactions in drug: poloxamer solid dispersions Int J Pharm 391 162 168 20214957 10.1016/j.ijpharm.2010.03.014 1:CAS:528:DC%2BC3cXltFCnsL8%3D
42. S Sharma P Sher S Badve AP Pawar 2005 Adsorption of meloxicam on porous calcium silicate: characterization and tablet formulation AAPS PharmSciTech 6 4 E618 E625 16408863 10.1208/pt060476 (Pubitemid 41819443)
43. K Evangelos G Emmanouel B Dimitrios 2006 Felodipine nanodispersions as active core for predictable pulsatile chronotherapeutics using PVP/HPMC blends as coating layer Int J Pharm 313 189 197 10.1016/j.ijpharm.2006.01.015